Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03372057 · ClinicalTrials.gov registry record · Phase 2
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT03372057 is a Phase 2 study of Peripheral T-Cell Lymphoma that has completed, run by SecuraBio. The registered enrollment target is 156 participants, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (53% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT03372057, a Phase 2 study of Peripheral T-Cell Lymphoma, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Conditions Studied
Interventions
- DRUG Duvelisib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California - Irvine - Irvine
- University of California - Los Angeles - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester - Rochester
- Stony Brook Cancer Center - Stony Brook
North Carolina
- Levine Cancer Institute - Charlotte
- Novant Health - Charlotte
- Duke University - Durham
Ohio
- The Ohio State University - Columbia
- Toledo Cancer Center - Toledo
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Feinberg School of Medicine - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2023-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03372057
The ClinicalTrials.gov registry entry for NCT03372057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (53% higher). The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Duvelisib is the first listed.
NCT03372057 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03372057 about?
NCT03372057 is a clinical study titled "A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
What is the current status of trial NCT03372057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2018-02-22. Estimated completion is 2023-12-22.
What conditions does trial NCT03372057 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT03372057?
The interventions under investigation include: Duvelisib (DRUG).
Who is sponsoring clinical trial NCT03372057?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03372057 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.